1. Home
  2. NOG vs MESO Comparison

NOG vs MESO Comparison

Compare NOG & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Oil and Gas Inc.

NOG

Northern Oil and Gas Inc.

HOLD

Current Price

$21.28

Market Cap

2.3B

Sector

Energy

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.61

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOG
MESO
Founded
2006
2004
Country
United States
Australia
Employees
64
81
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.8B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
NOG
MESO
Price
$21.28
$16.61
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$31.14
N/A
AVG Volume (30 Days)
3.9M
220.4K
Earning Date
04-28-2026
02-26-2026
Dividend Yield
6.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,475,723,000.00
N/A
Revenue This Year
$14.07
$629.74
Revenue Next Year
$4.24
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
11.23
N/A
52 Week Low
$17.18
$12.66
52 Week High
$31.17
$21.50

Technical Indicators

Market Signals
Indicator
NOG
MESO
Relative Strength Index (RSI) 58.83 58.87
Support Level $20.57 $13.82
Resistance Level $22.86 $17.33
Average True Range (ATR) 0.70 0.66
MACD 0.47 0.30
Stochastic Oscillator 97.74 53.53

Price Performance

Historical Comparison
NOG
MESO

About NOG Northern Oil and Gas Inc.

Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: